Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes of ravulizumab in adults and pediatric pa...

Full description

Bibliographic Details
Main Authors: Bradley P. Dixon, David Kavanagh, Alvaro Domingo Madrid Aris, Brigitte Adams, Hee Gyung Kang, Edward Wang, Katherine Garlo, Masayo Ogawa, Praveen Amancha, Sourish Chakravarty, Nils Heyne, Seong Heon Kim, Spero Cataland, Sung-Soo Yoon, Yoshitaka Miyakawa, Yosu Luque, Melissa Muff-Luett, Kazuki Tanaka, Larry A. Greenbaum
Format: Article
Language:English
Published: Elsevier 2024-08-01
Series:Kidney Medicine
Subjects:
Adult
atypical hemolytic uremic syndrome
complement C5 inhibitor
efficacy
hematology
nephrology
Online Access:http://www.sciencedirect.com/science/article/pii/S2590059524000669

Internet

http://www.sciencedirect.com/science/article/pii/S2590059524000669

Similar Items